Targeting CD19 in B-cell lymphoma: Emerging role of SAR3419

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 225-233

  Raufi, Ali ^a   Ebrahim, Abdul Shukkur ^a   Al Katib, Ayad ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody drug conjugates (ADC); Lymphoma; Maytansinoids; Microtubule inhibitors; SAR3419

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CD19 ANTIGEN; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; MAYTANSINE; MONOCLONAL ANTIBODY; MYC PROTEIN; OFATUMUMAB; PREDNISONE; RITUXIMAB; SAR 3419; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLURRED VISION; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER REGRESSION; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DRUG APPROVAL; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EYE TOXICITY; HUMAN; INTERNALIZATION; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; RADIOIMMUNOTHERAPY; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

EID: 84883377128     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S45957     Document Type: Review

References (75)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013, CA Cancer J Clin. 2013;63(1):11-30.
2. Howlader N, Noone AM, Krapcho M, etal (editors). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). [webpage on the Internet]. Bethesda, MD: National Cancer Institute; 2011 [updated Apr 2012]. Available from: http://seer.cancer.gov/csr/1975-2009_pops09/. Assessed July 10, 2013.
3. Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC; 2008.
4. Hallek M, Cheson BD, Catovsky D, etal. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
5. Owen RG, Treon SP, Al-Katib A, etal. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom'sMacroglobulinemia. Semin Oncol. 2003;30(2):110-115.
6. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
7. Ganem G, Cartron G, Girinsky T, Haas RL, Cosset JM, Solal-Celigny P. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys. 2010;78(4):975-982.
8. National Comprehensive Cancer Network [homepage on the Internet]. NCCN Clinical Practice Guidelines in Oncology: NCCN Non-Hodgkin's lymphoma Guidelines Version 1.2013. Available from: http://www.nccn.org/professionals/physician gls/f guidelines.asp. Accessed July 10, 2013.
9. Hiddemann W, Kneba M, Dreyling M, etal. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12): 3725-3732.
10. Persky DO, Unger JM, Spier CM, etal. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258-2263.
11. Habermann TM, Weller EA, Morrison VA, etal. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127.
12. Hagberg H, Gisselbrecht C; for CORAL study group: Randomized phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17(Suppl 4): iv31-iv32.
13. Stiff PJ, Unger JM, Cook J, etal. Randomized phase III US/Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma. J Clin Oncol. 2011;29(Suppl; abstract a8001).
14. Vitolo U, Chiappella A, Brusamolino E, etal. A randomized multicentre phase III study for first line treatment of young patients with high-risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): Rituximab ® plus dose-dense chemotherapy CHOP14/megaCHOP14 with or without intensified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial of Italian Lymphoma Foundation (FIL). Annals of Oncology. 2011;22(Suppl 4)a072:iv106.
15. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
16. Solal-Céligny P, Roy P, Colombat P, etal. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
17. Hoster E, Dreyling M, Klapper W, etal. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.
18. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1(2):118-129.
19. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today. 2003;8(11):503-510.
20. Trail PA, Bianchi AB. Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol. 1999;11(5):584-588.
21. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-1146.
22. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17(20):6389-6397.
23. Alley SC, Okeley NM, Senter PD: Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4): 529-537.
24. Reff ME, Carner K, Chambers KS, etal. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83(2):435-445.
25. Dillman RO. Magic bullets at last! Finally-approval of a monoclonal antibody for the treatment of cancer!!! Cancer Biother Radiopharm. 1997;12(4):223-225.
26. Coiffier B, Lepage E, Briere J, etal. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
27. Ghielmini M, Schmitz SF, Cogliatti SB, etal. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood. 2004;103(12):4416-4423.
28. Marcus R, Imrie K, Belch A, etal. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423.
29. Byrd JC, Peterson BL, Morrison VA, etal. Randomized phase 2study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6-14.
30. Keating MJ, Flinn I, Jain V, etal. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-3561.
31. Zinzani PL, Tani M, Pulsoni A, etal. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol. 2012;23(2):415-420.
32. Zinzani PL, Rossi G, Franceschetti S, etal. Phase II trial of short course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res. 2010;16(15):3998-4004.
33. Kaminski MS, Tuck M, Estes J, etal. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5): 441-449.
34. Kaminski MS, Tuck M, Estes J, etal. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced stage, follicular lymphoma: median 10 year follow-up results. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3759.
35. Younes A, Bartlett NL, Leonard JP, etal. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
36. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):572-577.
37. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol. 2005;560:125-139.
38. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol. 1992;149(9):2841-2850.
39. Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and Surface CD19signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol. 2012;189(5): 2318-2325.
40. van Zelm MC, Reisli I, van der Burg M, etal. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354(18):1901-1912.
41. Nadler LM, Anderson KC, Marti G, etal. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol. 1983;131(1):244-250.
42. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18(5-6): 385-397.
43. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63(6):1424-1433.
44. Carter RH, Myers R. Germinal center structure and function: lessons from CD19. Semin Immunol. 2008;20(1):43-48.
45. Lutz RJ, Zuany-Amorim C, Vrignaud P, Mayo MF, Guerif S, Xie H, et al. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphoma. Proc Am Assoc Cancer Res. 2006;47:3731.
46. Gerber HP, Kung-Sutherland M, Stone I, etal. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and-resistant lymphomas. Blood. 2009;113(18):4352-4361.
47. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993;70(1):62-67.
48. Mohamed AN, Al-Katib A. Establishment and characterization of a human lymphoma cell line (WSU-NHL) with 14; 18 translocation. Leuk Res. 1988;12(10):833-843.
49. Mohammad RM, Mohamed AN, KuKuruga M, Smith MR, Al-Katib A. A human B-cell lymphoma line with de novo multidrug resistance phenotype. Cancer. 1992;69(6):1468-1474.
50. Al-Katib A, Mohammad RM, Mohamed AN. WSU-BL: a new Burkitt's lymphoma cell line with capacity to differentiate in vitro. Ann NY Acad Sci. 1989;567:317-319.
51. Mohamed AN, Mohammad RM, Koop BF, Al-Katib A. Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL). Cancer. 1989;64(5):1041-1048.
52. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9): 3077-3080.
53. Taub R, Kirsch I, Morton C, etal. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79(24): 7837-7841.
54. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7824-7827.
55. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol. 2004;22:55-79.
56. Monroe JG. ITAM-mediated tonic signaling through pre-BCR and BCR complexes. Nat Rev Immunol. 2006;6(4):283-294.
57. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest. 2012;122(6):2257-2266.
58. Pillay V, Gan HK, Scott AM. Antibodies in oncology. N Biotechnol. 2011;28(5):518-529.
59. Pillay V, Allaf L, Wilding AL, etal. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia. 2009;11(5):448-458.
60. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011;8(2):85-96 [Erratum in: Nat Rev Clin Oncol. 2011;8(3):124].
61. Kupchan SM, Komoda Y, Court WA, etal. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc. 1972;94(4):1354-1356.
62. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science. 1975;189(4207): 1002-1005.
63. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17(20):6448-6458.
64. Chabner BA, Levine AS, Johnson BL, Young RC. Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep. 1978;62(3): 429-433.
65. Blum RH, Kahlert T. Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep. 1978;62(3):435-438.
66. Cabanillas F, Rodriguez V, Hall SW, Burgess MA, Bodey GP, Freireich EJ. Phase I study of maytansine using a 3-day schedule. Cancer Treat Rep. 1978;62(3):425-428.
67. Eagan RT, Ingle JN, Rubin J, Frytak S, Moertel CG. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. J Natl Cancer Inst. 1978;60(1):93-96.
68. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev. 1978;5(4): 199-207.
69. Erickson HK, Park PU, Widdison WC, etal. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426-4433.
70. Kovtun YV, Audette CA, Ye Y, etal. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214-3221.
71. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res. 2009;15(12):4038-4045.
72. DiJoseph JF, Goad ME, Dougher MM, etal. Potent and specific antitumor efficacy of CMC-544, aCD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res. 2004;10(24):8620-8629.
73. Younes A, Kim S, Romaguera J, etal. Phase I multi-dose escalation study of the anti-CD19maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012;30(22): 2776-2782.
74. Coiffier B, Ribrag V, Dupuis J, etal. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2011;29(suppl; abstract 8017).
75. Carol H, Szymanska B, Evans K, etal. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res. 2011;19(7):1795-1805.